Very late scaffold thrombosis after everolimus-eluting bioresorbable scaffold implantation in patients with unremarkable interim surveillance angiography.

[1]  H. Schunkert,et al.  Midterm clinical outcomes with everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents for percutaneous coronary interventions: a meta-analysis of randomised trials. , 2018, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[2]  Patrick W Serruys,et al.  Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary. , 2018, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[3]  L. Räber,et al.  Mechanisms of Very Late Bioresorbable Scaffold Thrombosis: The INVEST Registry. , 2017, Journal of the American College of Cardiology.

[4]  P. Serruys,et al.  Late thrombotic events after bioresorbable scaffold implantation: a systematic review and meta-analysis of randomized clinical trials , 2017, European heart journal.

[5]  P. Serruys,et al.  2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy , 2017, The Lancet.

[6]  P. Serruys,et al.  Dmax for sizing, PSP-1, PSP-2, PSP-3 or OCT guidance: interventionalist's jargon or indispensable implantation techniques for short- and long-term outcomes of Absorb BRS? , 2017, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[7]  J. Tijssen,et al.  Bioresorbable Scaffolds versus Metallic Stents in Routine PCI , 2017, The New England journal of medicine.

[8]  Patrick W Serruys,et al.  Possible mechanical causes of scaffold thrombosis: insights from case reports with intracoronary imaging. , 2017, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[9]  Bernard Chevalier,et al.  Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial , 2016, The Lancet.

[10]  Hiroki Shiomi,et al.  Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial. , 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[11]  W. Cheong,et al.  1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis , 2016, The Lancet.

[12]  A. Schmermund,et al.  Bioresorbable Coronary Scaffold Thrombosis: Multicenter Comprehensive Analysis of Clinical Presentation, Mechanisms, and Predictors. , 2016, Journal of the American College of Cardiology.

[13]  Heribert Schunkert,et al.  Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials , 2016, The Lancet.

[14]  R. Virmani,et al.  Pathological aspects of bioresorbable stent implantation. , 2015, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[15]  T. Münzel,et al.  Immediate, acute, and subacute thrombosis due to incomplete expansion of bioresorbable scaffolds. , 2014, JACC. Cardiovascular interventions.

[16]  R. Virmani,et al.  Long-Term Safety of an Everolimus-Eluting Bioresorbable Vascular Scaffold and the Cobalt-Chromium XIENCE V Stent in a Porcine Coronary Artery Model , 2014, Circulation. Cardiovascular interventions.

[17]  G. Stone,et al.  The clinical impact of routine angiographic follow-up in randomized trials of drug-eluting stents: a critical assessment of "oculostenotic" reintervention in patients with intermediate lesions. , 2010, JACC. Cardiovascular interventions.

[18]  Adnan Kastrati,et al.  Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. , 2009, Journal of the American College of Cardiology.

[19]  P. Serruys,et al.  Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions , 2007, Circulation.